摘要
Abstract
Objective To systematically review the efficacy and safety of megestrol acetate for improving the quality of life in patients with advanced cancer.Methods Studies related to megestrol acetate in the treatment of advanced cancer and anorexia-cachexia syndrome published from 2012 to 2022 in the PubMed,The Cochrane Library,ClinicalTrials.gov,Web of Science,Embase,CNKI,CBM and WanFang databases were searched.The studies were screened according to the inclusion and exclusion criteria,and the Cochrane tool,and the Transparent Reporting of Evaluations with Nonrandomized Designs(TREND)were used to assess the quality and bias risk of randomized controlled trials(RCTs)and quasi-experimental studies(QES).The RevMan 5.3 software was used for Meta-analysis.Results A total of 24 studies were included,involving 1 815 patients,including five RCTs and nineteen QES.Meta-analysis results showed that compared with those in the group receiving only conventional treatment,the body mass significantly increased[OR=7.04,95％CI(5.31,9.33),P＜0.000 01],the appetite significantly improved[OR=10.85,95％CI(8.09,14.56),P＜0.000 01],and the Karnofsky performance score(KPS)score significantly improved[OR=6.36,95％CI(4.74,8.54),P＜0.000 01]in the group receiving conventional treatment+megestrol acetate.Megestrol acetate for the treatment of advanced cancer involved 487 patients,with 54 cases(11.09％)of adverse reactions,the most common being concave edema of the extremities(3.90％).Conclusion Megestrol acetate can increase body mass,improve appetite,and quality of life in patients with advanced cancer,with good safety.关键词
醋酸甲地孕酮/晚期肿瘤/厌食症-恶病质综合征/生活质量/安全性/系统评价Key words
megestrol acetate/advanced cancer/anorexia-cachexia syndrome/quality of life/safety/systematic review分类
医药卫生
